Clinical Trials Browser

INDUSTRY × Basal Cell Nevus Syndrome × Dermatologic × Clear all

NCT06050122 2025-10-14

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Phase 3 Active not recruiting

Basal Cell Nevus Syndrome

NCT04308395 2024-09-24

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Phase 3 Terminated

108 enrolled 12 charts

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT04893486 2024-08-29

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Phase 2 Completed

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03703310 2024-07-03

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Phase 3 Completed

174 enrolled 23 charts

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT04416516 2024-04-10

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Phase 2 Completed

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT04155190 2023-05-31

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Phase 2 Terminated

Rombo syndrome, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Syndrome, Xeroderma Pigmentosum

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Phase 1/2 Suspended

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

Phase 2 Completed

17 enrolled 22 charts

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

Phase 2 Completed

36 enrolled 17 charts

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02550678 2018-06-06

ASN-002-001

Phase 1/2 Completed

Basal Cell Nevus Syndrome, Skin Neoplasms

NCT03070691 2017-05-05

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Phase 2/3 Withdrawn

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02002689 2016-05-02

SIGNATURE

Phase 2 Terminated

10 enrolled 9 charts

DermatologicGastrointestinalGynecologicOther hematologic neoplasm

Basal Cell Nevus Syndrome, Colonic Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT00961896 2015-11-03

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Phase 2 Completed

18 enrolled 13 charts

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT01350115 2015-10-19

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Phase 2 Completed

10 enrolled 9 charts

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT00049959 2011-03-16

Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.

Phase 3 Terminated

Basal cell carcinoma, multiple, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell